Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Boehringer Ingelheim

Clinicaltrial registered30 Oct 2026

Boehringer Ingelheim

30 Oct 2026: Trial registered · A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
30 Oct 2026
Title
A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People
Conditions
Healthy
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
Germany
Country
Germany
Reference
NCT07908004
Location
Germany
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Boehringer Ingelheim

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Boehringer Ingelheim in our registers.

More from Germany

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.